0000000001038198

AUTHOR

Giordana Bettini

showing 11 related works from this author

Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary

2020

medicine.medical_specialtyBisphosphonate-associated osteonecrosis of the jawOncology (nursing)business.industryHealth PolicyMEDLINEGuidelinemedicine.diseaseClinical PracticeOncologymascc isoo ascoo mrojHumansMedicineBisphosphonate-Associated Osteonecrosis of the JawbusinessOsteonecrosis of the jawIntensive care medicineJCO Oncology Practice
researchProduct

Proceedings of the Closed Round Table and Italian Consensus on the Medication-Related Osteonecrosis of Jaws (MRONJ) at the Symposium of Italian Socie…

2019

Part iiimedicine.medical_specialtyRound tablebusiness.industryPhysiologyGeneral surgeryPhysiology (medical)Oral and maxillofacial pathologymedicineItalian Consensus Medication-Related OsteoNecrosis of Jaws MRONJmedicine.diseasebusiness
researchProduct

RE: MEDICATION-RELATED OSTEONECROSIS OF THE JAW (MRONJ)

2021

OrthodonticsOtorhinolaryngologybusiness.industrySection (typography)medicineMEDLINESurgeryOral SurgeryOsteonecrosis of the jawmedicine.diseasebusinessJournal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
researchProduct

Proceedings of the Closed Round Table and Italian Consensus on the Medication-Related Osteonecrosis of Jaws (MRONJ) at the Symposium of Italian Socie…

2019

On 20 October 2018 a Closed Round Table brought together a wide range of stakeholders from several medical disciplines, including academic experts, dentists, oncologists, maxillo-facial surgeons, oral surgeons, radiologists, under the technical and scientific coordination of Giuseppina Campisi (for SIPMO) and Giacomo Oteri (for Italian Society of Oral Surgery- SIdCO).

Settore ING-IND/14 - Progettazione Meccanica E Costruzione Di MacchinePhysiologySettore MED/28 - Malattie OdontostomatologichePhysiology (medical)italian consensus mroj
researchProduct

Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020

2020

The Medication-Related Osteonecrosis of Jaws (MRONJ) diagnosis process and its prevention play a role of great and rising importance, not only on the Quality of Life (QoL) of patients, but also on the decision-making process by the majority of dentists and oral surgeons involved in MRONJ prevention (primary and secondary). The present paper reports the update of the conclusions from the Consensus Conference—held at the Symposium of the Italian Society of Oral Pathology and Medicine (SIPMO) (20 October 2018, Ancona, Italy)—after the newest recommendations (2020) on MRONJ were published by two scientific societies (Italian Societies of Maxillofacial Surgery and Oral Pathology and Medicine, SI…

bisphosphonateOral SurgeonHealth Toxicology and Mutagenesislcsh:MedicineMRONJantiangiogenic agents; antiresorptive drugs; bisphosphonates; cancer; denosumab; dentistry; MRONJ; oral surgery; osteoporosis; prevention models; bisphosphonate-associated osteonecrosis of the jaw; bone density conservation agents; diphosphonates; humans; Italy; quality of life0302 clinical medicineprevention modelCancerantiangiogenic agentsdentistryBone Density Conservation AgentsDiphosphonatesConference ReportBisphosphonatesAntiresorptive DrugsDenosumabItaly030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawDenosumabmedicine.drugoral surgerymedicine.medical_specialtyOral surgery03 medical and health sciencesOral surgeryAntiangiogenic agentsOral and maxillofacial pathologymedicinecancerHumansantiangiogenic agentantiresorptive drugsIntensive care medicinePrevention modelsbisphosphonatesantiresorptive drugAntiangiogenic agentsbusiness.industrylcsh:RPublic Health Environmental and Occupational Healthdenosumab030206 dentistrymedicine.diseaseosteoporosisAntiresorptive drugsDentistryOsteoporosisprevention modelsbusinessAntiangiogenic agents; Antiresorptive drugs; Bisphosphonates; Cancer; Denosumab; Dentistry; MRONJ; Oral surgery; Osteoporosis; Prevention models
researchProduct

BRONJ in patients with rheumatoid arthritis: A multicenter case series

2016

Objective: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of various medications (bisphosphonates, anti-resorptive, and anti-angiogenic drugs). ONJ pathogenesis is still unclear although some risk factors have been recognized. Of these, rheumatoid arthritis (RA) has been hypothesized as a potential risk factor for developing ONJ. This observational study will describe a multicenter case series of patients affected with RA and ONJ, and it will attempt to evaluate the association between features of ONJ and pharmacological, systemic, and site variables. Methods: Demographic, pharmacological, and clinical data from 18 RA patients with ONJ were collected and registered fr…

Malemedicine.medical_specialtymedicine.medical_treatmentOsteoporosisONJArthritis Rheumatoid03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansBisphosphonateONJ; Bisphosphonate; Denosumab; Jaw; Osteonecrosis; Osteoporosis; Rheumatoid arthritis; Dentistry (all); Otorhinolaryngology2734 Pathology and Forensic MedicineRheumatoid arthritisAdverse effectGeneral DentistryRheumatoid arthritiAgedBisphosphonate-associated osteonecrosis of the jawbusiness.industryOtorhinolaryngology2734 Pathology and Forensic MedicineOsteoporosiOsteonecrosis030206 dentistryBisphosphonateMiddle Agedmedicine.diseaseSurgeryDenosumabOtorhinolaryngologyJaw030220 oncology & carcinogenesisRheumatoid arthritisOsteonecrosiDentistry (all)OsteoporosisMethotrexateBisphosphonate-Associated Osteonecrosis of the JawFemaleDenosumabbusinessOsteonecrosis of the jawmedicine.drug
researchProduct

MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series

2023

Abstract Background Cancer treatment-induced bone loss (CTIBL) is the most common adverse event experienced by patients affected by breast cancer (BC) patients, without bone metastases. Bone modifying agents (BMAs) therapy is prescribed for the prevention of CTIBL, but it exposes patients to the risk of MRONJ. Methods This multicentre hospital-based retrospective study included consecutive non-metastatic BC patients affected by MRONJ related to exposure to low-dose BMAs for CTIBL prevention. Patients’ data were retrospectively collected from the clinical charts of seven recruiting Italian centres. Results MRONJ lesions were found in fifteen females (mean age 67.5 years), mainly in the mandi…

Bone modifying agentsBreast cancerOsteonecrosis of the jawCancer treatment-induced bone lossONJCTIBLMRONJGeneral DentistryBone modifying agents; Breast cancer; CTIBL; Cancer treatment-induced bone loss; MRONJ; ONJ; Osteonecrosis of the jawBMC Oral Health
researchProduct

Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multic…

2015

Osteonecrosis of the jaw (ONJ) associated with the use of bisphosphonates has been rarely reported in metastatic renal cell cancer (RCC) patients. Since the introduction of combined therapies consisting of nitrogen-containing bisphosphonates (NBPs) and targeted agents, an increasing number of RCC patients were reported to develop ONJ, suggesting that therapeutic angiogenesis suppression might increase the risk of ONJ in NBPs users. We performed a multicenter retrospective study and reviewed literature data to assess the occurrence and to investigate the nature of ONJ in RCC patients taking NBPs and targeted agents. Nine Italian Centers contributed to the data collection. Patients with expos…

MaleOncologyIndolesAngiogenesis InhibitorsPyrroleBevacizumab; m-TOR inhibitor; Sorafenib; Sunitinib; Zoledronic acidRetrospective StudieAntineoplastic Combined Chemotherapy ProtocolsSunitinibAged 80 and overDiphosphonatesSunitinibImidazolesOsteonecrosisKidney NeoplasmMiddle AgedSorafenibKidney NeoplasmsBevacizumabDiphosphonateItalyOncologyOsteonecrosiFemaleAngiogenesis InhibitorHumanmedicine.drugSorafenibmedicine.medical_specialtyBevacizumab; m-TOR inhibitor; Sorafenib; Sunitinib; Zoledronic acid; Aged; Aged 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Indoles; Italy; Jaw; Kidney Neoplasms; Male; Middle Aged; Osteonecrosis; Pyrroles; Retrospective Studies; Oncology; UrologyBevacizumabUrologyInternal medicinemedicineHumansPyrrolesIn patientMetastatic renal cell cancerImidazoleCarcinoma Renal CellZoledronic acidAgedRetrospective StudiesAntineoplastic Combined Chemotherapy Protocolbusiness.industryRetrospective cohort studymedicine.diseasem-TOR inhibitorSurgeryZoledronic acidJawIndolebusinessOsteonecrosis of the jaw
researchProduct

Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease

2014

AbstractManagement of osteonecrosis of the jaw associated with antiresorptive agents is challenging, and outcomes are unpredictable. The severity of disease is the main guide to management, and can help to predict prognosis. Most available staging systems for osteonecrosis, including the widely-used American Association of Oral and Maxillofacial Surgeons (AAOMS) system, classify severity on the basis of clinical and radiographic findings. However, clinical inspection and radiography are limited in their ability to identify the extent of necrotic bone disease compared with computed tomography (CT). We have organised a large multicentre retrospective study (known as MISSION) to investigate th…

AdultMaleCutaneous FistulaSettore MED/50 - Scienze Tecniche Mediche ApplicateDental Fistulastaging system; bisphosphonate; computed tomography; aaoms; osteonecrosis of the jaw; antiresorptive agentsAAOMSAntiresorptive agentSettore MED/29 - Chirurgia MaxillofaccialeAAOMS Antiresorptive agents Bisphosphonate Computed tomography Osteonecrosis of the jaw Staging systemBronj; AAOMS; Antiresorptive agents; Bisphosphonate; Computed tomography; Osteonecrosis of the jaw; Staging systemSettore MED/28 - Malattie OdontostomatologicheMandibular FracturesBronjOsteonecrosis of the jaw; Bisphosphonate; Staging system; AAOMS; Computed tomography; Antiresorptive agentsAlveolar ProcessHumansBisphosphonateMandibular DiseasesComputed tomographyAgedRetrospective StudiesAged 80 and overSuppurationBone Density Conservation AgentsOsteonecrosis of the jawPatient AcuityAntiresorptive agentsCone-Beam Computed TomographyMiddle AgedStaging systemMaxillary DiseasesPhenotypeOtorhinolaryngologyTooth ExtractionBisphosphonate-Associated Osteonecrosis of the JawDrug Therapy CombinationFemaleSurgeryOsteonecrosis of the jaw; Bisphosphonate; Staging system; AAOMS; Computed tomography; Antiresorptive agentsAAOMS; Antiresorptive agents; Bisphosphonate; Computed tomography; Osteonecrosis of the jaw; Staging systemOral SurgeryTomography X-Ray ComputedTomography Spiral ComputedOsteosclerosis
researchProduct

Proceedings of the Closed Round Table and Italian Consensus on the Medication-Related Osteonecrosis of Jaws (MRONJ) at the Symposium of Italian Socie…

2019

On 20 October 2018 a Closed Round Table brought together a wide range of stakeholders from several medical disciplines, including academic experts, dentists, oncologists, maxillo-facial surgeons, oral surgeons, radiologists, under the technical and scientific coordination of Giuseppina Campisi (for SIPMO) and Giacomo Oteri (for Italian Society of Oral Surgery- SIdCO)

SIPMOBRONJ (bisphosphonate-related osteonecrosis of the jaw)Risk of inappropriatenessSIdCOPhysiologyPhysiology (medical)Italian consensus mrojMRONJ Italian ConsensusMRONJONJ (osteonecrosis of the jaws)BRONJ (bisphosphonate-related osteonecrosis of the jaw)Risk of inappropriatenessMRONJ Italian ConsensusSIPMOSIdCOMRONJONJ (osteonecrosis of the jaws)
researchProduct

Comment on “Medication-Related Osteonecrosis of the Jaw (MRONJ)” by Elie M. Ferneini in the Section “Simply Put: JOMS Information for Patients”

2021

We read with great interest the contribute to the section “Simply Put: JOMS Information for Patients” named “Medication-Related Osteonecrosis of the Jaw (MRONJ)” by Elie M. Ferneini.

Comment medication-related osteonecrosis of the jaw mronj
researchProduct